The volatility ratio for the week is 17.47%, and the volatility levels for the last 30 days are 12.73% for Zenas Biopharma Inc The simple moving average for the past 20 days is -27.15% for ZBIO’s stock, with a -22.50% simple moving average for the past 200 days.
Is It Worth Investing in Zenas Biopharma Inc (NASDAQ: ZBIO) Right Now?
Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZBIO is 9.87M, and at present, short sellers hold a 6.44% of that float. On November 19, 2024, the average trading volume of ZBIO was 174.66K shares.
ZBIO) stock’s latest price update
The stock price of Zenas Biopharma Inc (NASDAQ: ZBIO) has dropped by -11.81 compared to previous close of 17.11. Despite this, the company has seen a fall of -29.06% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-
Analysts’ Opinion of ZBIO
Many brokerage firms have already submitted their reports for ZBIO stocks, with Rodman & Renshaw repeating the rating for ZBIO by listing it as a “Buy.” The predicted price for ZBIO in the upcoming period, according to Rodman & Renshaw is $34 based on the research report published on November 05, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see ZBIO reach a price target of $40. The rating they have provided for ZBIO stocks is “Overweight” according to the report published on October 08th, 2024.
Jefferies gave a rating of “Buy” to ZBIO, setting the target price at $35 in the report published on October 08th of the current year.
ZBIO Trading at -22.50% from the 50-Day Moving Average
After a stumble in the market that brought ZBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.52% of loss for the given period.
Volatility was left at 12.73%, however, over the last 30 days, the volatility rate increased by 17.47%, as shares sank -35.04% for the moving average over the last 20 days.
During the last 5 trading sessions, ZBIO fell by -29.06%, in comparison to the 20-day moving average, which settled at $20.71. In addition, Zenas Biopharma Inc saw -16.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZBIO starting from MOULDER LEON O JR, who purchase 10,000 shares at the price of $17.91 back on Sep 18 ’24. After this action, MOULDER LEON O JR now owns 1,662,039 shares of Zenas Biopharma Inc, valued at $179,100 using the latest closing price.
MOULDER LEON O JR, the Chief Executive Officer of Zenas Biopharma Inc, purchase 5,000 shares at $18.45 during a trade that took place back on Sep 20 ’24, which means that MOULDER LEON O JR is holding 1,672,039 shares at $92,270 based on the most recent closing price.
Stock Fundamentals for ZBIO
The liquidity ratio also appears to be rather interesting for investors as it stands at 8.95.
Conclusion
To sum up, Zenas Biopharma Inc (ZBIO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
